IL162090A0 - Agents having a core peptide which derepresses iap-inhibited caspase and pharmaceutical compositionscontaining the same - Google Patents

Agents having a core peptide which derepresses iap-inhibited caspase and pharmaceutical compositionscontaining the same

Info

Publication number
IL162090A0
IL162090A0 IL16209002A IL16209002A IL162090A0 IL 162090 A0 IL162090 A0 IL 162090A0 IL 16209002 A IL16209002 A IL 16209002A IL 16209002 A IL16209002 A IL 16209002A IL 162090 A0 IL162090 A0 IL 162090A0
Authority
IL
Israel
Prior art keywords
derepresses
iap
agents
same
core peptide
Prior art date
Application number
IL16209002A
Other languages
English (en)
Original Assignee
Torrey Pines Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrey Pines Inst filed Critical Torrey Pines Inst
Publication of IL162090A0 publication Critical patent/IL162090A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL16209002A 2001-11-21 2002-11-21 Agents having a core peptide which derepresses iap-inhibited caspase and pharmaceutical compositionscontaining the same IL162090A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33195701P 2001-11-21 2001-11-21
PCT/US2002/037577 WO2003045974A2 (fr) 2001-11-21 2002-11-21 Methodes et compositions de derepression de caspase inhibee par un iap (inhibiteur de proteine d'apoptose)

Publications (1)

Publication Number Publication Date
IL162090A0 true IL162090A0 (en) 2005-11-20

Family

ID=23296076

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16209002A IL162090A0 (en) 2001-11-21 2002-11-21 Agents having a core peptide which derepresses iap-inhibited caspase and pharmaceutical compositionscontaining the same

Country Status (7)

Country Link
US (2) US6911426B2 (fr)
EP (1) EP1465649A4 (fr)
JP (1) JP2005510569A (fr)
CN (2) CN101029080A (fr)
CA (1) CA2467892A1 (fr)
IL (1) IL162090A0 (fr)
WO (1) WO2003045974A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060258581A1 (en) * 2001-11-21 2006-11-16 Reed John C Methods and composition for derepressions of IAP-inhibited caspase
CN101029080A (zh) * 2001-11-21 2007-09-05 伯纳姆研究院 用于对iap抑制卡斯蛋白酶进行去阻遏的方法及组合物
US7067274B2 (en) * 2003-11-13 2006-06-27 Genentech, Inc. Compositions and methods for the screening pro-apoptotic compounds
KR20060126548A (ko) * 2004-02-05 2006-12-07 노파르티스 아게 (ａ) ＤＮＡ 토포이소머라제 억제제 및 (ｂ) ＩＡＰ 억제제조합물
US7309792B2 (en) 2004-03-01 2007-12-18 Board Of Regents, The University Of Texas System Dimeric small molecule potentiators of apoptosis
US7618981B2 (en) * 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
US20100190688A1 (en) * 2004-07-12 2010-07-29 Bin Chao Tetrapeptide analogs
ES2475207T3 (es) 2004-07-15 2014-07-10 Tetralogic Pharmaceuticals Corporation Compuestos de unión a IAP
US20060019335A1 (en) * 2004-07-20 2006-01-26 Chunying Du Compositions and methods to promote c-IAP autodegradation
WO2006060898A1 (fr) * 2004-12-06 2006-06-15 Aegera Therapeutics Inc Technique de traitement de troubles inflammatoires
AU2006216450C1 (en) 2005-02-25 2013-01-10 Medivir Ab Dimeric IAP inhibitors
US20070003535A1 (en) * 2005-03-17 2007-01-04 Reed John C Methods and compositions for derepression of IAP-inhibited caspase
US20060276423A1 (en) * 2005-04-18 2006-12-07 Rachel Altura Survivin-directed RNA interference-compositions and methods
US7892737B2 (en) * 2005-06-30 2011-02-22 Life Technologies Corporation Compositions, kits and methods pertaining to stability modulation of PNA oligomer/nucleic acid complexes
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
JP2009542689A (ja) * 2006-07-07 2009-12-03 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 選択的カスパーゼ阻害剤
WO2008014236A1 (fr) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Inhibiteurs d'iap dimériques
WO2008014238A2 (fr) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Inhibiteurs des iap dimères
US8143426B2 (en) * 2006-07-24 2012-03-27 Tetralogic Pharmaceuticals Corporation IAP inhibitors
WO2008014240A2 (fr) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Inhibiteurs des iap dimères
BRPI0715195A2 (pt) * 2006-07-24 2013-06-11 Tetralogic Pharm Corp composto, mÉtodos para induzir e para estimular a apoptose em uma cÉlula, para intensificar a apoptose de cÉlulas patogÊnicas in vivo em um indivÍduo, e para tratar uma doenÇa, e, composiÇço farmacÊutica
US8283372B2 (en) * 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4006180A (en) * 1973-10-12 1977-02-01 Merck & Co., Inc. [1,3-Dihydroxy-2-substituted and 2,2-disubstituted-indanyloxy(or thio)]alkanoic acids
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE69130831T2 (de) 1990-11-21 1999-09-16 Iterex Pharmaceuticals Ltd. Partnership, San Diego Synthese äquimolarer mischungen vielzähliger oligomere, speziell oligopeptidmischungen
US5766848A (en) * 1993-01-04 1998-06-16 Synaptic Pharmaceutical Corporation Methods for identifying compounds which specifically bind a human betaine/GABA transporter
US6228603B1 (en) 1997-05-22 2001-05-08 The Burnham Institute Screening assays for agents that alter inhibitor of apoptosis (IAP) protein regulation of caspase activity
JP4068666B2 (ja) * 1997-05-22 2008-03-26 ザ バーナム インスティチュート カスパーゼ活性のアポトーシスインヒビター（ｉａｐ）タンパク質調節を変える薬剤についてのスクリーニングアッセイ
US6159709A (en) 1998-07-24 2000-12-12 Apoptogen, Inc. XIAP IRES and uses thereof
US6570069B1 (en) * 2000-02-10 2003-05-27 Regents Of The University Of California Nucleic acids encoding plant inhibitors of apoptosis and transgenic cells and plants expressing them
AU2002248309A1 (en) * 2001-01-08 2002-07-16 The Burnham Institute Inhibitor of apoptosis proteins and nucleic acids and methods for making and using them
US20050119176A1 (en) * 2001-11-21 2005-06-02 The Burnham Institute Methods and compositions for derepression of IAP-inhibited caspase
CN101029080A (zh) * 2001-11-21 2007-09-05 伯纳姆研究院 用于对iap抑制卡斯蛋白酶进行去阻遏的方法及组合物

Also Published As

Publication number Publication date
WO2003045974A2 (fr) 2003-06-05
US20050159359A1 (en) 2005-07-21
CA2467892A1 (fr) 2003-06-05
CN101029080A (zh) 2007-09-05
CN1615148A (zh) 2005-05-11
US20030180805A1 (en) 2003-09-25
EP1465649A2 (fr) 2004-10-13
AU2002359457A1 (en) 2003-06-10
EP1465649A4 (fr) 2007-07-11
US6911426B2 (en) 2005-06-28
WO2003045974A3 (fr) 2004-02-19
AU2002359457A2 (en) 2003-06-10
JP2005510569A (ja) 2005-04-21

Similar Documents

Publication Publication Date Title
IL162090A0 (en) Agents having a core peptide which derepresses iap-inhibited caspase and pharmaceutical compositionscontaining the same
GB0012671D0 (en) Therapeutic agents
GB0004003D0 (en) Therapeutic agents
GB0122666D0 (en) Well planning and design
TW539393U (en) 089204149
EP1423399A4 (fr) Chelateurs d'hydroxypyridonate et d'hydroxypyrimidinone
GB0005789D0 (en) Therapeutic agents
GB0025473D0 (en) Pharmaceutical combinations
HUP0300334A3 (en) Pharmaceutical preparations and their manufacture
EP1293131A4 (fr) Agents therapeutiques pour la gorge
GB0020721D0 (en) Therapeutic agents
GB0012291D0 (en) Pharmaceutical combination
GB0017518D0 (en) Therapeutic agents
HUP0302826A3 (en) Synergistic herbicidal mixtures and use thereof
GB2365032B (en) A sectional structure and parts thereof
AU8252101A (en) Oct preparations
GB0017543D0 (en) Therapeutic agents
GB0018887D0 (en) Compound and their therapeutic use
IL152158A0 (en) A glycopeptide and preparation thereof
GB0222473D0 (en) Well planning and design
GB0104243D0 (en) Floodstoppers 2
GB0021487D0 (en) Pharmaceutical
GB0018619D0 (en) Therapeutic agents
GB0012709D0 (en) Therapeutic agents
GB0004626D0 (en) Therapeutic agents